NHLBI clinical trials workshop: An executive summary

Statistics in Medicine

Volumn 31, Issue 25, 2012, Pages 2938-2943

  Zheng, Gang ^a   Wu, Colin O ^a   Yang, Song ^a   Waclawiw, Myron A ^a   Demets, David L ^b   Geller, Nancy L ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Adaptive design; Bayesian clinical trials; Comparative effectiveness research; Genomic trials; Missing data; Personalized medicine; Reporting clinical trials; Surrogate endpoints

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BAYES THEOREM; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; DATA COLLECTION METHOD; DISEASE MARKER; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; GENOMICS; HEALTH CARE COST; HISTORY; HUMAN; INFORMATION PROCESSING; INTENTION TO TREAT ANALYSIS; MEDICAL RESEARCH; MEDICAL SOCIETY; PERSONALIZED MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STUDY DESIGN; WORKSHOP;

CLINICAL TRIALS AS TOPIC; HISTORY, 20TH CENTURY; HUMANS; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (U.S.); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH PERSONNEL; UNITED STATES;

EID: 84867440072     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5406     Document Type: Article

References (18)

1. Greenberg Report. Organization, review, and administration of cooperative studies (Greenberg Report): a report from the Heart Special Project Committee to the National Advisory Heart Council, May 1967. Controlled Clinical Trials 1988; 9:137-148.
2. Coronary Drug Project Research Group. The Coronary Drug Project: findings leading to further modifications of its protocol with respect to dextrothyroxine. JAMA 1972; 220:996-1008.
3. Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. NEJM 1980; 303(18):1038-1041.
4. Biswas S, Liu DD, Lee JJ, Berry DA. Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clinical Trials 2009; 6:205-216.
5. Schulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine 2010; 152:1-8.
6. National Research Council."Front Matter." The Prevention and Treatment of Missing Data in Clinical Trials. The National Academies Press: Washington, DC, 2010. 1. Print.
7. Zhang J, Heitjan DF. Nonignorable censoring in randomized clinical trials. Clinical Trials 2005; 2:488-496.
8. Zhang J, Heitjan DF. A simple sensitivity analysis tool for noningorable coarsening: Application to dependent censoring. Biometrics 2006; 62:1260-1268.
9. Zhang J, Heitjan DF. Impact of nonignorable coarsening on Bayesian inference. Biostatistics 2007; 8:722-743.
10. Committee on National Statistics. Handling Missing Data in Clinical Trials, Division of Behavioral and Social Sciences and Education, The National Academies, 2009. www8.nationalacademies.org.
11. Kaitin KI. Tufts Center for the Study of Drug Development impact report. May/June 2010; 12(3).
12. Office of Communication, Division of Drug Information, Center for Drug Evaluation and Research, Food and Drug Administration. Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics, 2010. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM201790.pdf.
13. Cohen JC, Kiss RS, Pertsemlidis A, Marcel YL, McPherson R, Hobbs HH. Multiple rare alleles contribute to low plasma levels of HDL cholesterol. Science 2004; 305:869-872.
14. Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against Type 1 diabetes. Science 2009; 324:387-389.
15. Freidlin B, Simon R. Adaptive signature design. Clinical Cancer Research 2005; 11:7872-7878.
16. Freidlin B, Jiang W, Simon R. Cross-validated adaptive signature design. Clinical Cancer Research 2010; 16:691-698.
17. Clancy C, Collins FS. Patient-Centered Outcomes Research Institute: The intersection of science and health care. Science Translational Medicine 2010; 2:37cm18.
18. Institute of Medicine committee on Comparative Effectiveness Research Prioritization. Initial National Priorities of Comparative Effectiveness Research. Institute of Medicine of the National Academies. June 30, 2009, http://www.iom.edu/Reports/2009/ComparativeEffectivenessResearchPriorities.aspx.